Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 08:30 ET | Source: MeiraGTx

MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update

LONDON and NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the...
October 31, 2018 08:30 ET | Source: MeiraGTx

MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia

LONDON and NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced an exclusive...
October 25, 2018 08:30 ET | Source: MeiraGTx

MeiraGTx Expands Leadership Team with Appointment of Katherine Breedis as Chief Financial Officer

LONDON and NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that on October 2nd, 2018,...
October 16, 2018 08:00 ET | Source: MeiraGTx

MeiraGTx Enters Collaboration with Johnson & Johnson Innovation to Develop Regulatable Gene Therapy Treatment using MeiraGTx Riboswitch Technology

LONDON and NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has entered into a...
October 09, 2018 07:00 ET | Source: MeiraGTx

MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease

LONDON and NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has acquired Vector...
October 02, 2018 16:30 ET | Source: MeiraGTx

MeiraGTx to Present at Upcoming Conferences

LONDON and NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it will...
August 27, 2018 08:00 ET | Source: MeiraGTx

MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsia

LONDON and NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Offices...
August 20, 2018 08:00 ET | Source: MeiraGTx

MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia

LONDON and NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food...
August 13, 2018 07:00 ET | Source: MeiraGTx

MeiraGTx Announces AAV-CNGA3 Has Received Orphan Drug Designation from the U.S. FDA for the Treatment of Achromatopsia

LONDON and NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food...
August 08, 2018 08:00 ET | Source: MeiraGTx

MeiraGTx Reports Second Quarter 2018 Financial Results and Provides Corporate Update

LONDON and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the...